US companies partner to investigate metabolomics of Alzheimer’s disease

Skip to Navigation

News

  • Published: Jul 18, 2016
  • Author: Jon Evans
  • Source: Muses Labs
  • Channels: HPLC / Base Peak

Muses Labs is partnering with Metabolon, a US metabolomics company, to investigate metabolomics in individuals with pre- and early-symptomatic cognitive decline and Alzheimer’s disease. The companies expect to bring new clinical trial services and updated care protocols to the market in 2016.

“Muses Labs’ protocols utilize a patient’s genome, blood tests, medical history and lifestyle to direct care. Metabolomics adds additional significant insight into a patient’s biological status to improve identification of active pathologies and enable further refinement of patient care programs,” said Vik Chandra, CEO of Muses Labs. “Metabolomics has the potential to significantly expand the effectiveness of combination therapy protocols for Alzheimer’s and other complex diseases. Our collaboration with Metabolon has the power to advance precision medicine in this area.”

“We’re working together to expand the knowledge we can apply toward overcoming Alzheimer’s disease,” said John Ryals, CEO of Metabolon. “Our goal is to use our proprietary technology in conjunction with Muses Labs’ personalized Protocols to provide clinicians with a more accurate health assessment of patients experiencing cognitive decline as well as more actionable information. Metabolomics may help answer questions that surround complex, neurodegenerative diseases and refine personalized treatment.” Metabolon investigates metabolomics using its proprietary DiscoveryHD4 platform, which includes liquid chromatography-tandem mass spectrometry.

“While research into metabolomics and Alzheimer’s disease is in its early stages, we believe that by using this technology, the connections between metabolism and the underlying pathologies of Alzheimer's disease will become better understood,” said Marwan Sabbagh, research professor of Neurology at the University of Arizona College of Medicine and chief medical-scientific advisor at Muses Labs. “Metabolomics can guide the clinical care of Alzheimer’s disease today while laying the foundation for new interventions and protocols.”

Social Links

Share This Links

Bookmark and Share

Microsites

Suppliers Selection
Societies Selection

Banner Ad

Click here to see
all job opportunities

Most Viewed

Copyright Information

Interested in separation science? Visit our sister site separationsNOW.com

Copyright © 2017 John Wiley & Sons, Inc. All Rights Reserved